

# Journal of Visualized Experiments

## A novel nicotinamide adenine dinucleotide correction method for intracellular Ca<sup>2+</sup> measurement with fura-2-analog in live cells

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59881R4
Full Title:	A novel nicotinamide adenine dinucleotide correction method for intracellular Ca <sup>2+</sup> measurement with fura-2-analog in live cells
Keywords:	Mitochondria; Calcium; Fura-2-FF; Mitochondrial membrane potential; NADH; pH; Calibration equation
Corresponding Author:	Chae Hun Leem KOREA, REPUBLIC OF
Corresponding Author's Institution:	
Corresponding Author E-Mail:	leemch@gmail.com
Order of Authors:	Jeong Hoon Lee Jeong Mi Ha Quynh Mai Ho Chae Hun Leem
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed. Please do not use abbreviations.	Songpa-gu, Seoul, Korea

**TITLE:**

A Novel Nicotinamide Adenine Dinucleotide Correction Method for Intracellular  $\text{Ca}^{2+}$  Measurement with Fura-2-Analog in Live Cells

**AUTHORS AND AFFILIATIONS:**

Jeong Hoon Lee<sup>1</sup>, Jeong Mi Ha<sup>1</sup>, Quynh Mai Ho<sup>1</sup>, Chae Hun Leem<sup>1,2,3</sup>

<sup>1</sup>Department of Physiology, University of Ulsan College of Medicine/Asan Medical Center, Seoul, Korea

<sup>2</sup>Asan Medical Center, Seoul, Korea

<sup>3</sup>Asan Medical Institute of Convergence Science and Technology, Seoul, Korea

Corresponding author:

Chae Hun Leem (leemch@amc.seoul.kr; leemch@gmail.com)

Email addresses of co-authors:

Jeong Hoon Lee (biobodhi@gmail.com)

Jeong Mi Ha (jmha@amc.seoul.kr)

Quynh Mai Ho (quynhmaiho88@gmail.com)

**KEYWORDS:**

mitochondria, calcium, fura-2-FF, mitochondrial membrane potential, NADH, pH, calibration equation

**SUMMARY:**

Due to the spectral overlapping of the excitation and emission wavelengths of NADH and fura-2 analogs, the signal interference from both chemicals in live cells is unavoidable during quantitative measurement of  $[\text{Ca}^{2+}]$ . Thus, a novel online correction method of NADH signal interference to measure  $[\text{Ca}^{2+}]$  was developed.

**ABSTRACT:**

To measure  $[\text{Ca}^{2+}]$  quantitatively, fura-2 analogs, which are ratiometric fluoroprobes, are frequently used. However, dye usage is intrinsically limited in live cells because of autofluorescence interference, mainly from nicotinamide adenine dinucleotide (NADH). More specifically, this is a major obstacle when measuring the mitochondrial  $[\text{Ca}^{2+}]$  quantitatively using fura-2 analogs because the majority of NADH is in the mitochondria. If the fluorescent dye concentration is the same, a certain excitation intensity should produce the same emission intensity. Therefore, the emission intensity ratio of two different excitation wavelengths should be constant. Based on this principle, a novel online correction method of NADH signal interference to measure  $[\text{Ca}^{2+}]$  was developed, and the real signal intensity of NADH and fura-2 can be obtained. Further, a novel equation to calculate  $[\text{Ca}^{2+}]$  was developed with isosbestic excitation or excitation at 400 nm. With this method, changes in mitochondrial  $[\text{Ca}^{2+}]$  could be successfully measured. In addition, with a different set of the excitation and emission wavelengths, multiple parameters, including NADH,  $[\text{Ca}^{2+}]$ , and pH or mitochondrial membrane

potential ( $\Psi_m$ ), could be simultaneously measured. Mitochondrial  $[Ca^{2+}]$  and  $\Psi_m$  or pH were measured using fura-2-FF and tetramethylrhodamine ethyl ester (TMRE) or carboxy-seminaphthorhodafluor-1 (carboxy-SNARF-1).

## INTRODUCTION:

The significant role of intracellular  $Ca^{2+}$  is widely known<sup>1</sup>. The quantification of  $[Ca^{2+}]$  is essential to understand the processes of the cellular physiological functions. Fura-2 analogs are quite useful because they are excited in the UV range ( $<400$  nm), and the ratiometric method can be applied for the quantitative measurement. Therefore, other physiological parameters such as pH, membrane potential, etc., can be measured with other fluorescent dyes. The mitochondrial  $Ca^{2+}$  concentration ( $[Ca^{2+}]_m$ ) range was reportedly  $0.08\text{--}20\ \mu M$ <sup>2-5</sup>. Among fura-2 analogs, fura-2-FF is appropriate for measuring this range of  $[Ca^{2+}]$ . However, the live cells unfortunately contain NADH/NADPH for their metabolic processes, and NADH generates signal interference because of the overlapping excitation and emission spectra with the fura-2 analog. This interference greatly limits the use of fura-2 analogs. Specifically, if the analog is applied to measure mitochondrial  $[Ca^{2+}]$ , this interference is the biggest obstacle because the highest amount of NADH is in the mitochondria. This is further complicated by NADH changes being related to the mitochondrial membrane potential ( $\Psi_m$ ) and the change of  $\Psi_m$  affects  $[Ca^{2+}]_m$ <sup>6-9</sup>. Furthermore, for studying  $[Ca^{2+}]_m$  dynamics, it is essential to know the status of other mitochondrial parameters, such as NADH,  $\Psi_m$ , and pH.

The emissions at 450 nm and 500 nm with excitations at 353 nm, 361 nm, and 400 nm contain the signals from NADH and fura-2-FF, and the equations are as follows. Herein, 353 nm and 361 nm are the isosbestic points of fura-2-FF for emissions at 450 nm and at 500 nm, respectively.

$$F_{361,450} = F_{361,450,NADH} + F_{361,450,Fura} \quad \text{Equation 1}$$

$$F_{353,500} = F_{353,500,NADH} + F_{353,500,Fura} \quad \text{Equation 2}$$

$$F_{400,500} = F_{400,500,NADH} + F_{400,500,Fura} \quad \text{Equation 3}$$

where  $F_{x,y}$  is the measured emission intensity at y-nm by x-nm excitation,  $F_{x,y,NADH}$  represents the pure NADH-dependent emission intensity, and  $F_{x,y,Fura}$  represents the pure fura-2-FF-dependent emission intensity. Under the same concentration of the fluorescent dye, a certain excitation intensity should produce the same emission intensity. Therefore, the emission intensity ratio of two different excitation wavelengths should be constant.  $Ca^{2+}$  and fura-2 did not affect NADH fluorescence characteristics; therefore, the ratio of the emission at 450 nm and at 500 nm of NADH was constant at any excitation wavelength. The same rule can be used for fura-2-FF based on the assumption that NADH or  $[Ca^{2+}]$  does not affect the emission and excitation spectra of fura-2-FF. However,  $Ca^{2+}$  caused a spectral shift of the fura-2-FF emission. Therefore, to remove the effect of  $Ca^{2+}$ , isosbestic excitation, which is independent of  $Ca^{2+}$ , needs to be used. Each emission wavelength (i.e., 450 nm and 500 nm) has a different isosbestic point, and from our experimental setup, 353 nm at 500 nm and 361 nm at 450 nm were chosen. From these, the following equations are valid<sup>10</sup>.

$$R_f = F_{361,450,Fura} / F_{353,500,Fura} \quad \text{Equation 4}$$

$$R_{N1} = F_{400,500,NADH}/F_{361,450,NADH}$$

Equation 5

$$R_{N2} = F_{353,500,NADH}/F_{361,450,NADH}$$

Equation 6

With these constants, the following equations from (Equation 1) (Equation 2), and (Equation 3) are valid.

$$F_{361,450} = F_{361,450,NADH} + R_f \times F_{353,500,Fura}$$

Equation 7

$$F_{353,450} = R_{N2} \times F_{361,450,NADH} + F_{353,500,Fura}$$

Equation 8

$$F_{400,500} = R_{N1} \times F_{361,450,NADH} + F_{400,500,Fura}$$

Equation 9

From these equations, if  $R_f$ ,  $R_{N1}$ , and  $R_{N2}$  are known, pure signals of NADH and fura-2 can be obtained as follows.

$$F_{361,450,NADH} = (F_{361,450} - R_f \times F_{353,500}) / (1 - R_f \times R_{N2})$$

Equation 10

$$F_{353,500,Fura} = (R_{N2} \times F_{361,450} - F_{353,500}) / (R_f \times R_{N2} - 1)$$

Equation 11

$$F_{400,500,Fura} = F_{400,500} - R_{N1} \times F_{361,450,NADH}$$

Equation 12

$$R_{Fura} = F_{353,500,Fura} / F_{400,500,Fura}$$

Equation 13

The  $Ca^{2+}$ -bound form of fura-2-FF was practically non-fluorescent at the 400 nm excitation wavelength. Based on this property, the following new calibration equation can be derived.

$$[Ca^{2+}] = K_d \cdot (F_{400,500,max} / F_{353,500,max}) \times (R_{Fura} - R_{min})$$

Equation 14

where  $K_d$  is a dissociation constant,  $F_{400,500,max}$  and  $F_{353,500,max}$  are the maximum values of the emitted signals at 500 nm with excitations at 400 nm and 353 nm, respectively, and  $R_{min}$  is the minimum  $R_{Fura}$  in  $Ca^{2+}$ -free condition. Since the isosbestic excitations were used, the equation can be simplified further as follows.

$$[Ca^{2+}] = K_d \cdot (1 / R_{min}) \cdot (R_{Fura} - R_{min})$$

Equation 15

Therefore, only  $K_d$  and  $R_{min}$  values are required to calculate  $[Ca^{2+}]$ .

## PROTOCOL:

All experimental protocols were approved by the local institutional animal care and use committee.

### 1. Solution preparation

1.1. Prepare single freshly isolated cardiac myocytes<sup>11</sup>.

NOTE: Each laboratory might have a different cell storage solution. Here, the myocytes are stored in culture medium (DMEM).

1.2. Prepare 100 mL of  $\text{Ca}^{2+}$ -free solution (**Table 1**).

1.3. Prepare 50 mL of culture medium in a 50 mL beaker. Aliquot 5 mL and put it in a water bath at 37 °C. Keep the remaining solution at room temperature.

1.4. Prepare 50 mL of the saponin solution by adding 5 mg of saponin to 50 mL of  $\text{Ca}^{2+}$ -free solution.

NOTE: Saponin is used to permeabilize cardiac myocytes, to remove cytosolic compartments, and to visualize the mitochondrial fluorescence only.

1.5. Prepare 16  $\mu\text{L}$  of 1 mM fura-2-FF-AM dissolved in dimethyl sulfoxide (DMSO).

NOTE: Make 1 mM stock solution of fura-2-FF-AM dissolved in DMSO and aliquot 16  $\mu\text{L}$  in a 2 mL tube. Store them at -20 °C until use.

1.6. Prepare 50 mL of NADH-free  $\text{Ca}^{2+}$ -free solution (**Table 1**) and 50 mL of NADH-free  $\text{Ca}^{2+}$ -saturated solution (**Table 1**) when isosbestic points are to be measured. Adjust pH to 7.0 with KOH.

NOTE: NADH-free  $\text{Ca}^{2+}$ -free solution (**Table 1**) contains 10  $\mu\text{M}$  FCCP and 100  $\mu\text{M}$  ADP without any mitochondrial substrates to minimize NADH in mitochondria.

1.7. Prepare 50 mL of  $\text{Ca}^{2+}$ -free solution, 50 mL of malate solution, 50 mL of pyruvate solution, 50 mL of malate-pyruvate solution, and 50 mL of rotenone solution to be used for NADH correction factor measurements (**Table 1**).

## 2. Fluoroprobe loading procedure into the mitochondria

2.1. Prepare the dye-loading solution by adding 2 mL of the culture medium to 16  $\mu\text{L}$  of 1 mM fura-2-FF-AM.

NOTE: Fluorescent dye is fragile under the light. Prepare the solution just before use. Keep the solution containing the fluorescent dye in a dark place. The final concentration of fura-2-FF-AM is 8  $\mu\text{M}$ . If carboxy-SNARF-1 was used, prepare the dye loading solution with 2  $\mu\text{M}$  carboxy-SNARF-1-AM.

2.2. Take 2 mL of the isolated cells and place in a 5 mL test tube in an upright position.

2.3. Wait 15 min for myocytes to sink to the bottom and remove the supernatant.

NOTE: The supernatant may contain cell debris. Do not centrifuge the tube to avoid cell damage.

2.4. Add 2 mL of the dye-loading solution.

2.5. Incubate the dye-loading solution with cells for 60 min at 4 °C.

2.6. Then, put the test tube in a 37 °C water bath for 30 min in an upright position.

2.7. Remove the supernatant, and add 4 mL of the prewarmed culture medium of 37 °C. Incubate the cells for 60 min in a 37 °C water bath.

2.8. Finally, remove the supernatant, add 4 mL of culture medium at room temperature and keep the tube at room temperature.

### 3. Introduction of the multiparametric measurement system

NOTE: **Figure 1** shows a diagram of the whole system.

3.1. For an excitation light source, use a fast monochromator (polychrome II) that can change the light within 3 ms.

3.2. Use an oil immersion lens (40x, NA 1.3) with an inverted microscope to increase the signal intensity.

3.3. Use a near-infrared filter and a charge-coupled device (CCD) camera to monitor the object field without fluorescent signal interference.

3.4. Capture the object field image to get the area.

3.5. Adjust the object field in monitor screen with a field diaphragm just to show the cell for reducing the background.

3.6. Use four photomultiplier tubes with each band-pass filter (450, 500, 590, and 640 nm) to detect emission wavelengths with photon counting method. Use the appropriate dichroic mirrors to split and to redirect the emission light.

NOTE: The excitation light is very strong compared to the emission light. Thus, choose the band-pass filter with the highest blocking characteristics to reduce the background. A photon counting system comprises a combination of PMTs, photon counter units, and a high-speed counter. To control the system and to sample the data, a custom-made driving software was used. Finding a way to apply this method with other systems is necessary.

### 4. NADH correction methods with a multiparametric measurement system

4.1. The background signal detection and the correction methods with the cell area

NOTE: There are two kinds of backgrounds. One comes from the cells and the other comes from

the reflection on the cover slip (the cell-free background). Both backgrounds need to be corrected in each experiment.

4.1.1. Mount the dye-free cells in the bath on the microscope and wait 3 min for cells to sink to the bottom. Perfuse NADH-free  $\text{Ca}^{2+}$ -free solution for around 5 min.

NOTE: The perfusion rate of all solutions is 2-3 mL/min at 37 °C. Adjust cell numbers to see around one cell per one objective field with a 40x objective lens.

4.1.2. Set the object field to cover the targeted cell.

4.1.3. After moving the cell out of the field, measure the background signals of the cell-free window and set them as offsets.

NOTE: The signal means the light signal to be detected in the photon counting system.

4.1.4. Return the cell to the initial position and measure the cell background signals and the cell area.

NOTE: Even though the excitation light is filtered with the bandpass filter, it still contains a large amount of the filtered light. This light is dispersed when hitting the cells and causes considerable background signals because the photon counting system is highly sensitive. It needs to be corrected. The cell area may be calculated with a captured cell image and available imaging software. The unit of the cell area can be any unit including pixel count. Only standardization is necessary.

4.1.5. Repeat steps 4.1.1 to 4.1.4 10 times to obtain the relationship between the cell area and the cell background signals.

NOTE: Later, the cell background signals can be calculated from the cell area from the relationship. Since the excitation light bulb ages, this procedure needs to be repeated, at least, every month.

4.2. Identification of the isosbestic points of fura-2-FF in situ

NOTE: Many reports have stated that fluorescent characteristics are changed in cells. Therefore, perform all procedures to obtain the parameters to correct the interference in situ.

4.2.1. Mount the dye-loaded cell on the microscope and wait 3 min for cells to sink to the bottom.

NOTE: Adjust cell numbers to see around one cell per one objective field with a 40x objective lens.

4.2.2. Perfuse the NADH-free  $\text{Ca}^{2+}$ -free solution at 37 °C.

4.2.3. After targeting the cell, measure the cell-free background and the cell area as shown in section 4.1. Calculate the cell background from the cell area.

NOTE: Both background signals need to be corrected in each experiment.

4.2.4. Perfuse the saponin solution for 60 s and return to the NADH-free  $\text{Ca}^{2+}$ -free solution.

4.2.5. Measure fura-2-FF-emitted signals at 450 nm and 500 nm simultaneously by the excitation scan from 350 nm to 365 nm with a 0.1 nm step.

4.2.6. Perfuse the NADH-free  $\text{Ca}^{2+}$ -saturated solution and repeat step 4.2.5.

4.2.7. Subtract the signals in the  $\text{Ca}^{2+}$ -saturated solution from the signals in the  $\text{Ca}^{2+}$ -free conditions.

4.2.8. Repeat steps 4.2.2 to 4.2.7 with other single cardiac myocytes.

NOTE: If the signal intensity become weaker, repeat from step 4.2.1. Repeat the procedure for, at least, 5 different cells.

4.2.9. From all obtained signals, calculate the standard deviations of the emission at each excitation and choose the excitation wavelength, showing the minimum standard deviation (SD) value as an isosbestic point.

NOTE: The representative figures are shown in **Figure 2**.

#### 4.3. Measurement of R factors

4.3.1. Calculate  $R_f$  with equation 4 from the signals obtained in section 4.2.

4.3.2. Mount the dye-free cells on the microscope and perfuse the  $\text{Ca}^{2+}$ -free solution.

4.3.3. Measure the signals such as  $F_{361, 450, \text{NADH}}$ ,  $F_{400, 500, \text{NADH}}$ ,  $F_{361, 450, \text{NADH}}$ , and  $F_{353, 500, \text{NADH}}$ .

4.3.4. Perfuse the malate solution. Repeat step 4.3.3 and measure the signals.

4.3.5. Perfuse the pyruvate solution. Repeat step 4.3.3 and measure the signals.

4.3.6. Perfuse the malate-pyruvate solution. Repeat step 4.3.3 and measure the signals.

4.3.7. Perfuse the rotenone solution. Repeat step 4.3.3 and measure the signals.

NOTE: The example of the NADH signal recorded on 5 mM pyruvate, 5 mM malate plus 5 mM pyruvate, and 10  $\mu\text{M}$  rotenone addition is shown in **Figure 3**.



4.3.8. Calculate each slope of  $F_{361, 450, \text{NADH}}$  vs.  $F_{400, 500, \text{NADH}}$  and  $F_{361, 450, \text{NADH}}$  vs.  $F_{353, 500, \text{NADH}}$ . As shown in **Figure 3**. Each slope indicates  $R_{N1}$  and  $R_{N2}$ .

## 5. Selection of the excitation and the emission light for TMRE or carboxy-SNARF-1

5.1. If TMRE for measuring the mitochondrial potential was used in addition, use the 530 nm excitation wavelength and the 590 nm emission wavelength.

5.2. If carboxy-SNARF-1 for measuring the mitochondrial potential was used in addition, use the excitation wavelength of 540 nm and emission wavelengths of 590 nm and 640 nm<sup>12</sup>.

## 6. Selection of $K_d$ value of fura-2-FF

6.1. The change of pH can affect  $K_d$  values for  $\text{Ca}^{2+}$  binding on fura-2-FF<sup>10</sup>. Use the  $K_d$  value of 5.28 at pH 7.5 for the mitochondria.

## REPRESENTATIVE RESULTS:

Mitochondrial  $\text{Ca}^{2+}$  changes due to correction<sup>10</sup>

**Figure 4** shows the changes in  $[\text{Ca}^{2+}]_m$  before and after the correction. The results clearly showed the substantial changes in  $[\text{Ca}^{2+}]_m$ . The mitochondrial resting calcium concentration without cytosolic  $\text{Ca}^{2+}$  ( $[\text{Ca}^{2+}]_c$ ) was  $1.03 \pm 0.13 \mu\text{M}$  (mean  $\pm$  S.E.,  $n = 32$ ), and the maximum  $[\text{Ca}^{2+}]_m$  at  $1\text{-}\mu\text{M}$   $[\text{Ca}^{2+}]_c$  was  $29.6 \pm 1.61 \mu\text{M}$  (mean  $\pm$  S.E.,  $n = 33$ ) (**Figure 5**).

Simultaneous measurement of NADH,  $[\text{Ca}^{2+}]$ , and  $\Psi_m$ <sup>10</sup>

A positively charged TMRE can be distributed in a membrane potential-dependent manner. Membrane potential can be calculated using the Nernst's equation with the concentration in each compartment. The mitochondrial TMRA was monitored with the perfusion of 2-nM TMRE. The initial  $\Psi_m$  was assumed to be  $-150$  mV, and the change of  $\Psi_m$  was calculated based on that. The application of  $\text{Ca}^{2+}$  decreased NADH but affected  $\Psi_m$  only negligibly (**Figure 6**).

Mitochondrial pH changes by the change in  $[\text{Ca}^{2+}]_m$ <sup>10</sup>

The mitochondrial pH with the additional loading of carboxy-SNARF-1 was monitored following  $\text{Ca}^{2+}$  changes (**Figure 7**). The mitochondrial pH was not affected by the increase in  $[\text{Ca}^{2+}]_m$ . The resting mitochondrial pH was  $7.504 \pm 0.047$  (mean  $\pm$  S.E.,  $n = 13$ ). From these results,  $5.28 \mu\text{M}$  was the chosen  $K_d$  value of fura-2-FF at pH 7.5.

## FIGURE & TABLE LEGENDS:

### Figure 1: A microfluorometry system for multiparametric measurement

The schematic diagram of the microfluorometry system was shown. The mounted cells were visualized via a CCD camera. Four different emission lights were detected with four PMTs via a photon counting system. This figure has been reproduced with permission from The Korean Journal of Physiology & Pharmacology<sup>10</sup>.

**Figure 2: Identification of isosbestic points**

(A) The red arrow points to the isosbestic point at the 450 nm emission wavelength. Fura-2 FF in the non-bound state is shown with a dotted line and in the  $\text{Ca}^{2+}$  bound state with a solid line. (B) The red arrow is pointed to the isosbestic point at the 500 nm emission wavelength. (C) The subtracted data of the signal at 450 nm in  $\text{Ca}^{2+}$ -free conditions from  $\text{Ca}^{2+}$ -free saturated conditions are shown. (D) The subtracted data of the signal at 500 nm in  $\text{Ca}^{2+}$ -free conditions from  $\text{Ca}^{2+}$ -free saturated conditions are shown. (E) Standard deviation data from graph C are shown. (F) Standard deviation data from graph D are shown. This figure has been reproduced with permission from The Korean Journal of Physiology & Pharmacology<sup>10</sup>.

**Figure 3: Measurement of  $R_N$  factors.**

(A) Changes in the NADH signal without fluorescent dye by applying various mitochondrial substrates were measured at 361 nm excitation and 450 nm emission wavelengths. (B) The NADH interference in the fura-2-FF signals,  $F_{400,500}$  (···) and  $F_{353,500}$  (—), were simultaneously monitored. (C) The relationships between  $F_{361,450,\text{NADH}}$  and  $F_{400,500,\text{NADH}}$  (o) and between  $F_{361,450,\text{NADH}}$  and  $F_{353,500,\text{NADH}}$  (●) are shown. The obtained slopes are represented as  $R_{N1}$  and  $R_{N2}$ , respectively. This figure has been reproduced with permission from The Korean Journal of Physiology & Pharmacology<sup>10</sup>.

**Figure 4: Results of NADH and fura-2-FF interference correction**

The change of the signals from before the correction (shown in the left panels) to after the correction (shown in the right panels). (A) NADH signals at the 450 nm emission wavelength. (B) Fura-2-FF signals at the 500 nm emission wavelength. The figure shows  $F_{400,500}$  (—),  $F_{353,500}$  (----), and the ratio of fura-2-FF (—). (C) The mitochondrial calcium concentration. The red dotted line indicates the zero. This figure has been reproduced with permission from The Korean Journal of Physiology & Pharmacology<sup>10</sup>.

**Figure 5: Resting  $[\text{Ca}^{2+}]_m$  without cytosolic  $\text{Ca}^{2+}$  and maximal steady state  $[\text{Ca}^{2+}]_m$  at 1  $\mu\text{M}$  cytosolic  $\text{Ca}^{2+}$**

Mitochondria were energized with the perfusion of malate-pyruvate solution. The steady state  $[\text{Ca}^{2+}]_m$  in a  $\text{Ca}^{2+}$ -free conditions and in 1  $\mu\text{M}$   $\text{Ca}^{2+}$  conditions were shown. The addition of 5 mM  $\text{Na}^+$  recovered NADH and reduced  $[\text{Ca}^{2+}]_m$  to the baseline. This figure has been reproduced with permission from The Korean Journal of Physiology & Pharmacology<sup>10</sup>.

**Figure 6: Simultaneous measurement of NADH,  $[\text{Ca}^{2+}]_m$ , and  $\Psi_m$**

Mitochondria were energized with the perfusion of malate-pyruvate solution. The changes of NADH,  $[\text{Ca}^{2+}]_m$  and  $\Psi_m$  were shown. The addition of 1  $\mu\text{M}$   $\text{Ca}^{2+}$  decreased NADH and increased  $[\text{Ca}^{2+}]_m$  but  $\Psi_m$  was not changed significantly. This figure has been reproduced with permission from The Korean Journal of Physiology & Pharmacology<sup>10</sup>.

**Figure 7: Simultaneous measurement of NADH,  $[\text{Ca}^{2+}]_m$ , and pH**

The repeated application of  $\text{Ca}^{2+}$  could induce the decrease of NADH and the increase of  $[\text{Ca}^{2+}]_m$  but the mitochondrial pH was not affected by the application of  $\text{Ca}^{2+}$ . The addition of  $\text{Na}^+$  could

return the NADH and  $[Ca^{2+}]_m$  to the baseline. This figure has been reproduced with permission from The Korean Journal of Physiology & Pharmacology<sup>10</sup>.

## Table 1: Solutions

### DISCUSSION:

The interference correction method was successfully developed for measuring the signals of NADH and fura-2 analogs. Exact measurement of the signals is essential for exact correction. However, the inherent nature of the fluorescent device produces a background signal unrelated to that of NADH of fura-2. The highest quality band-pass filter can only pass up to  $10^{-8}$  of the unwanted wavelengths of the light. However, the fluorescent signal from a single cell is very small, and the reflection of the excitation light after the band-pass filter is still strong enough to contaminate the actual fluorescent signals. Therefore, careful correction of the background signal is necessary.

Fura-2 has a loading problem to measure mitochondrial  $Ca^{2+}$ . First, it is not easy to load the dye specifically into the mitochondria, and nonspecific loading into another organelle could be erroneous. Mitochondrial  $Ca^{2+}$  concentration is generally higher than that of the cytosol, and the use of fura-2-FF with a high  $K_d$  value could avoid the contamination of cytosolic  $Ca^{2+}$  changes. The other problematic organelle is the sarcoplasmic reticulum (SR). However, the distribution volume differences (SR 3.5% vs. mitochondria 34%–36% in rat ventricular myocytes)<sup>13,14</sup> and the removal of ATP in experiments could compensate for the contamination from SR.

Our calibration equation (Equation 14 and 15) has many advantageous characteristics over Grynkiewicz's equation<sup>15</sup> as follows:

- 1) It requires only three parameters:  $K_d$ ,  $F_{400,500,max}/F_{353,500,max}$ , and  $R_{min}$ .
- 2) There is linearity of the ratio value to the  $Ca^{2+}$  concentration at a constant pH.
- 3) There is a relative error-free parameter in  $F_{400,500,max}/F_{353,500,max}$  compared with  $S_{f2}/S_{b2}$ <sup>15</sup>.
- 4) In Equation 15, only  $K_d$  and  $R_{min}$  are required if isosbestic excitation is used.
- 5) The calibration procedure to obtain the parameter is much simpler with Equation 15.

However, there is a limitation because  $Ca^{2+}$ -saturated fura-2-FF generates a very small emission. It causes an error. The new equation can be applied to  $[Ca^{2+}]$  concentrations up to 50x that of  $K_d$ .

In conclusion, a protocol was developed to successfully solve the existing problem of NADH and fura-2-FF interference. This method can measure  $Ca^{2+}$  dynamics more accurately. Multiparametric measurement system, particularly in the mitochondria, will help understand the mitochondrial physiology in a quantitative way.

### ACKNOWLEDGMENTS:

This work was partially supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1A6A3A01011832), by the Ministry of Science, ICT & Future Planning (2014M3A9D7034366) and by the Ministry of Trade, Industry & Energy (10068076).


**DISCLOSURES:**


The authors have no conflicts of interest to disclose.


**REFERENCES:**

1. Berridge, M. J., Bootman, M. D., Roderick, H. L. Calcium signalling: dynamics, homeostasis and remodelling. *Nature Reviews Molecular Cell Biology*. **4** (7), 517-529 (2003).
2. Miyata, H. *et al.* Measurement of mitochondrial free  $\text{Ca}^{2+}$  concentration in living single rat cardiac myocytes. *American Journal of Physiology*. **261** (4 Pt 2), H1123-1134 (1991).
3. Allen, S. P., Stone, D., McCormack, J. G. The loading of fura-2 into mitochondria in the intact perfused rat heart and its use to estimate matrix  $\text{Ca}^{2+}$  under various conditions. *Journal of Molecular Cellular Cardiology*. **24** (7), 765-773 (1992).
4. Griffiths, E. J., Halestrap, A. P. Pyrophosphate metabolism in the perfused heart and isolated heart mitochondria and its role in regulation of mitochondrial function by calcium. *Biochemical Journal*. **290** ( Pt 2), 489-495 (1993).
5. Crompton, M., Moser, R., Ludi, H., Carafoli, E. The interrelations between the transport of sodium and calcium in mitochondria of various mammalian tissues. *European Journal of Biochemistry*. **82** (1), 25-31 (1978).
6. Chance, B., Schoener, B., Oshino, R., Itshak, F., Nakase, Y. Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. *The Journal of Biological Chemistry*. **254** (11), 4764-4771 (1979).
7. Eng, J., Lynch, R. M., Balaban, R. S. Nicotinamide adenine dinucleotide fluorescence spectroscopy and imaging of isolated cardiac myocytes. *Biophysical Journal*. **55** (4), 621-630 (1989).
8. Brandes, R., Bers, D. M. Simultaneous measurements of mitochondrial NADH and  $\text{Ca}^{2+}$  during increased work in intact rat heart trabeculae. *Biophysical Journal*. **83** (2), 587-604 (2002).
9. Jo, H., Noma, A., Matsuoka, S. Calcium-mediated coupling between mitochondrial substrate dehydrogenation and cardiac workload in single guinea-pig ventricular myocytes. *Journal of Molecular Cellular Cardiology*. **40** (3), 394-404 (2006).
10. Lee, J. H., Ha, J. M., Leem, C. H. A Novel Nicotinamide Adenine Dinucleotide Correction Method for Mitochondrial  $\text{Ca}^{2+}$  Measurement with FURA-2-FF in Single Permeabilized Ventricular Myocytes of Rat. *Korean Journal of Physiology and Pharmacology*. **19** (4), 373-382 (2015).
11. Powell, T., Terrar, D. A., Twist, V. W. Electrical properties of individual cells isolated from adult rat ventricular myocardium. *Journal of Physiology*. **302**, 131-153 (1980).
12. Sun, B., Leem, C. H., Vaughan-Jones, R. D. Novel chloride-dependent acid loader in the guinea-pig ventricular myocyte: part of a dual acid-loading mechanism. *Journal of Physiology*. **495** ( Pt 1), 65-82 (1996).
13. Page, E. Quantitative ultrastructural analysis in cardiac membrane physiology. *American Journal of Physiology*. **235** (5), C147-158 (1978).
14. Page, E., McCallister, L. P., Power, B. Stereological measurements of cardiac ultrastructures implicated in excitation-contraction coupling. *Proceedings of the National Academy of Sciences of the United States of America*. **68** (7), 1465-1466 (1971).
15. Grynkiewicz, G., Poenie, M., Tsien, R. Y. A new generation of  $\text{Ca}^{2+}$  indicators with greatly improved fluorescence properties. *The Journal of Biological Chemistry*. **260** (6), 3440-3450


485 (1985).  
486














Figure6





Figure7



Name of Solutions	Concentration (mM)									
	KCl	HEPES	EGTA	CaCl <sub>2</sub>	M	P	R	FCCP	ADP	Saponin
Ca <sup>2+</sup> -free	150	10	1							
NADH-free Ca <sup>2+</sup> -free	150	10	1					0.01	0.1	
NADH-free Ca <sup>2+</sup> -Saturated	135	10		1				0.01	0.1	
Saponin	150	10	1							0.1mg/ml
Malate	145	10	1		5					
Pyruvate	145	10	1			5				
Malate-pyruvate	140	10	1		5	5				
Rotenone	140	10	1		5	5	0.01			
Culture Medium	Dulbecco's Modified Eagle's Medium (DMEM)									
Dye-loading	Add an 1mM Fura-2-FF-AM stock(16 μL) in the Culture medium (2 mL)									

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
	Axygen	MCT-200-C	2 mL Tube
2 mL eppendorf tube.			
AD/DA converter	Instrutech	ITC-18	Equipment
ADP, Adenosine 5'-diphosphate monopotassium salt dihydrate	Sigma-aldrich	A5285	Chemicals
Band pass filter	Ealing Electro-Optics, Inc	35-3920	Equipment, 640±11 nm
Band pass filter	Omega Optical	690-9823	Equipment, 590±15nm
Band pass filter	Omega Optical	500DF20-9916	Equipment, 500±20nm
Band pass filter	Chroma Technology Corp.	60685	Equipment, 450±30nm
Calcium chloride solution	Sigma-aldrich	21114	Chemicals
carboxy-SNARF-1(AM)	Invitrogen	C1272	Chemicals
Charge-coupled device (CCD) camera	Philips	FTM1800NH/HGI	Equipment
Dichroic mirror	Chroma Technology Corp.	86009	Equipment, Multiband dichroic mirror, Reflection : <400nm, 490±10, 560±10, Transmission : 460±15, 510±20, >580nm
Dichroic mirror	Chroma Technology Corp.	567DCXRU	Equipment, Reflection : <560nm, Transmission : > 580 nm
Dichroic mirror	Chroma Technology Corp.	480dclp	Equipment, Reflection : <470nm, Transmission : > 490 nm
Dichroic mirror	Chroma Technology Corp.	20728	Equipment, Multiband dichroic mirror, Reflection : <405nm, 470±30, Transmission : 430nm~520nm, > 640 nm
Dimethyl sulfoxide(DMSO)	Sigma-aldrich	154938	Chemicals
DMEM, Dulbecco's Modified Eagle's Medium	Sigma-aldrich	D5030	Chemicals
EGTA, Egtazic acid, Ethylene- bis(oxyethylenenitrilo)tetraacetic acid, Glycol ether diamine tetraacetic acid	Sigma-aldrich	E4378	Chemicals
FCCP, Mesoxalonitrile 4- trifluoromethoxyphenylhydrazone	Sigma-aldrich	21857	Chemicals
field diaphragm	Nikon	86506	Equipment
Fura-2-FF(AM)	TEFLABS	137	chemicals
Green tube	DWM		test tube
HEPES, 4-(2-Hydroxyethyl)piperazine-1- ethanesulfonic acid, N-(2- Hydroxyethyl)piperazine-N'-(2- ethanesulfonic acid)	Sigma-aldrich	H3375	Chemicals
High-speed counter	National Instruments	NI-6022	Equipment
Hot mirror	Chroma Technology Corp.	21002	Equipment, 50:50
Inverted microscope	Nikon	TE-300	Equipment
Malate	Sigma-aldrich	27606	Chemicals
Near infrared filter	Chroma Technology Corp.	D750/100X	Equipment, 750±100nm
Oil immersion lens	Nikon	MRF01400	40x, NA 1.3; Equipment
Photon counter unit	Hamamatsu	C3866	Equipment
Photon multiplier tube	Hamamatsu	R2949	Equipment
Polychrome II	Till Photonics	SA3/MG04	Equipment
Potassium chloride	Merck	1.04936	Chemicals
Potassium hydroxide solution	Sigma-aldrich	P4494	Chemicals
Pyruvate	Sigma-aldrich	107360	Chemicals
Rotenone	Sigma-aldrich	R8875	Chemicals
Saponin	Sigma-aldrich	S4521	Chemicals
TMRE, Tetramethylrhodamine, ethyl ester	Molecular probes	T669	Chemicals



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

A novel nicotinamide adenine dinucleotide correction method for intracellular Ca<sup>2+</sup> measurement with fura-2-analog in live cells.

Author(s):

Jeong Hoon Lee, Jeong Mi Ha, Quynh Mai Ho and Chae Hun Leem

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒

Standard Access

☐

Open Access

Item 2: Please select one of the following items:

☒

The Author is **NOT** a United States government employee.

☐

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐

The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

612542.6 For questions, please contact us at [submissions@jove.com](mailto:submissions@jove.com) or +1.617.945.9051.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole



## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	Chae Hun Leem	
Department:	Department of Physiology	
Institution:	University of Ulsan College of Medicine/Asan Medical Center,	
Title:	Professor	
Signature:		Date: 22nd Feb 2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

612542.6 For questions, please contact us at [submissions@jove.com](mailto:submissions@jove.com) or +1.617.945.9051.

## Editorial comments

The significant role of intracellular  $\text{Ca}^{2+}$  is widely known and does not need to be explained in detail.

I change as follows and add a reference.

The significant role of intracellular  $\text{Ca}^{2+}$  is widely known

Steps 1-2 of the protocol can be removed entirely to focus the manuscript on the dye loading and the signal correction. Your suggestion of having a note or one line step is sufficient as long as there is a citation. Tables 1 and 2 should remain in the manuscript. This is to allow others to find the resources to replicate the steps. If steps 1-2 remain in the protocol, additional details will be needed however.

I deleted the previous steps 1 and 2 and changed the preparation of the solution. All solution compositions are displayed in the separate table

As steps 3, 4, and 5 are the most important parts of the protocol and the manuscript, we ask that additional details be provided so others can replicate the protocol with high fidelity.

Such as how to detect the signals and how to get the cell area is the area of the device and the software. Each lab may have different configuration and different software. I just mention the principle to be used. Except the device dependent procedure, I tried to add the explanation in detail.

3.1: What does one stock of fura-2-FF-AM mean?

4.7: Please specify the dichroic mirrors by their characteristics instead of the model number.

5.1.1/5.2.1: How many cells are mounted and at what density?

Please specify the perfusion rate for all perfusion steps.

Please provide a short legend for Figures 1, 5, 6, and 7.

I added and changed as your comments. The solution perfusion rate and the temperature are clearly mentioned in the procedure at the beginning. Appropriate cell density is microscope dependent and therefore, I mentioned it as one cell per one objective field.

I added the legends in Figure 1, 5, 6, and 7.